Rznomics and SK Pharmateco Partner for RNA Gene Therapy

A memorandum of understanding (MOU) for a contract development and manufacturing partnership has been signed by Rznomics Inc., a South Korean biopharmaceutical company that specialises in the development of RNA-based gene therapeutics, and SK pharmteco, a global contract development, manufacturing, and analytical testing organisation serving both the small molecule and cell & gene therapy industry.

The multi-year agreement will create a strategic alliance between Rznomics and SK Pharmateco for the development and marketing of various gene therapy products. In order to facilitate a seamless transition from clinical to full-scale commercial manufacture of Rznomics' ribonucleic acid (RNA)-based biopharmaceuticals, SK pharmteco will supply technical knowledge and resources, including staff and infrastructure.

According to Andy Fenny, CFO of SK Pharmateco, "We are thrilled about the opportunity to partner with Rznomics on their groundbreaking initiatives." "By combining our significant expertise in gene therapy manufacturing with Rznomics' innovative RNA-based therapeutic approach, we believe this collaboration has the potential to deliver life-changing treatments to patients in need quickly."

"This partnership will mark late-stage development and manufacturing of our gene therapy pipeline to prepare the path towards Phase II and later stage clinical trials and potential commercialisation," stated Rznomics' President and CEO, Seong-Wook Lee. We're excited to collaborate closely with SK Pharmateco."